Journal Watch · Frontiers in Immunology · 2026

Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host.

However, most emerging biomarkers remain investigational and require prospective validation.

Ismaili NFrontiers in Immunology3 min readPharma relevance 95/100

DOI: 10.3389/fimmu.2026.1847526PMID: 42367810Study type: cohort / observational clinical study

TL;DR

However, most emerging biomarkers remain investigational and require prospective validation.

Key findings

  • Murine models have provided key insights into these resistance mechanisms and the immunomodulatory role of the gut microbiome.
  • Collectively, the data support a shift from single-analyte biomarkers toward integrative, dynamic, systems-level models for patient selection, heralding a new era of precision immune-oncology in GC.
  • However, most emerging biomarkers remain investigational and require prospective validation.

What they did

This review critically appraises these findings alongside established and emerging predictive biomarkers. We examine the strengths and limitations of PD-L1, MSI, TMB, and EBV status, and explore the clinical potential of dynamic tools like ctDNA and computational models. We also discuss emerging evidence on intrinsic resistance to PD-1 blockade in MSI-H GC, including PTEN mutations, low TMB within MSI-H tumors, and antigen presentation defects.

Full abstract (original)

Background: Immune checkpoint inhibitors (ICIs) have transformed advanced gastric cancer (GC) treatment, but durable responses remain rare, highlighting the need for better patient selection. Recent studies suggest that host-derived autoantibodies (e.g., ANA, ENA) may serve as prognostic markers in GC patients receiving immunotherapy. These hypothesis-generating observations indicate that pre-existing humoral immunity could reflect a clinically relevant axis of immune fitness.

What they did: This review critically appraises these findings alongside established and emerging predictive biomarkers. We examine the strengths and limitations of PD-L1, MSI, TMB, and EBV status, and explore the clinical potential of dynamic tools like ctDNA and computational models. We also discuss emerging evidence on intrinsic resistance to PD-1 blockade in MSI-H GC, including PTEN mutations, low TMB within MSI-H tumors, and antigen presentation defects.

Results & conclusions: Murine models have provided key insights into these resistance mechanisms and the immunomodulatory role of the gut microbiome. Collectively, the data support a shift from single-analyte biomarkers toward integrative, dynamic, systems-level models for patient selection, heralding a new era of precision immune-oncology in GC. However, most emerging biomarkers remain investigational and require prospective validation.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1847526 · PubMed 42367810.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery, microbiome therapeutics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery · microbiome therapeutics

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

However, most emerging biomarkers remain investigational and require prospective validation.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. This review critically appraises these findings alongside established and emerging predictive biomarkers.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1847526. PubMed ID: 42367810. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Ismaili N. Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1847526.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/rethinking-biomarker-strategy-in-gastric-cancer-immunotherapy-from-tumor-847526/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides